Zydus gets USFDA nod for chemotherapy drug
The drug will be produced at the group's manufacturing facility in Ahmedabad
 "Zydus gets USFDA nod for chemotherapy drug")
premium
Ahmedabad-based drug major Zydus Cadila today said that it has received approval from the US drug regulator for its chemotherapy drug methotrexate tablets for the US markets.
The company has received final approval from the US Food and Drug Administration (USFDA) to market methotrexate tablets (2.5 mg strength) in the US market that is used for treatement of leukaemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers
The drug will be produced at the group's manufacturing facility in Ahmedabad.
The group now has more than 105 approvals and has so far filed nearly 275 abbreviated new drug applications (ANDAs) since 2003-04.
Shares of Cadila Healthcare today ended at Rs 356.35 a share on the BSE, up 1.87 per cent from the previous close.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%